15 years of historical data (2011–2025) · Healthcare · Biotechnology
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Xencor, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $918M | $1.1B | $1.5B | $1.3B | $1.6B | $2.4B | $2.5B | $2.0B | $2.0B | $1.0B | $1.1B |
| Enterprise Value | $932M | $1.2B | $1.7B | $1.3B | $1.6B | $2.3B | $2.3B | $2.0B | $1.9B | $1.0B | $1.1B |
| P/E Ratio → | -10.30 | — | — | — | — | 29.28 | — | 74.76 | — | — | 47.00 |
| P/S Ratio | — | — | 13.53 | 7.36 | 9.44 | 8.82 | 20.34 | 12.83 | 48.04 | 28.74 | 12.75 |
| P/B Ratio | 0.75 | 0.89 | 2.22 | 1.92 | 2.14 | 3.31 | 4.36 | 3.39 | 3.74 | 3.64 | 3.55 |
| P/FCF | — | — | — | — | — | — | — | 37.70 | — | — | 12.18 |
| P/OCF | — | — | — | — | 63.44 | — | — | 31.23 | — | — | 11.79 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | 15.26 | 7.53 | 9.47 | 8.42 | 19.11 | 12.58 | 47.39 | 28.27 | 12.58 |
| EV / EBITDA | — | — | — | — | — | 45.21 | — | 108.77 | — | — | 45.87 |
| EV / EBIT | — | — | — | — | — | 28.04 | — | 142.59 | — | — | 23.87 |
| EV / FCF | — | — | — | — | — | — | — | 36.96 | — | — | 12.02 |
Margins and return-on-capital ratios measuring operating efficiency
Operating margins have compressed from -75.8% to -161.5% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -9.5% indicates the company is currently destroying shareholder equity.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | 100.0% | 100.0% | 100.0% | 100.0% | -38.4% | 24.3% | -140.1% | -101.0% | 40.7% |
| Operating Margin | — | — | -161.5% | -75.8% | -50.1% | 15.9% | -62.6% | 8.8% | -195.5% | -150.0% | 25.8% |
| Net Profit Margin | — | — | -210.5% | -76.2% | -33.5% | 30.0% | -56.5% | 17.2% | -173.4% | -137.0% | 27.0% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -9.5% | -9.5% | -34.6% | -19.1% | -7.6% | 12.7% | -11.9% | 4.8% | -17.5% | -16.4% | 9.9% |
| ROA | -10.1% | -10.1% | -24.4% | -14.8% | -6.6% | 10.7% | -10.1% | 4.3% | -14.6% | -12.0% | 7.4% |
| ROIC | — | — | -17.1% | -13.9% | -9.1% | 6.3% | -11.8% | 2.0% | -15.6% | -14.2% | 7.5% |
| ROCE | — | — | -20.6% | -16.0% | -10.6% | 6.5% | -13.0% | 2.5% | -19.6% | -17.5% | 9.3% |
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $14M ($68M total debt minus $54M cash).
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.05 | 0.05 | 0.34 | 0.12 | 0.08 | 0.05 | 0.02 | 0.02 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | 0.66 | — | 0.59 | — | — | — |
| Net Debt / Equity | — | 0.01 | 0.28 | 0.04 | 0.01 | -0.15 | -0.27 | -0.07 | -0.05 | -0.06 | -0.05 |
| Net Debt / EBITDA | — | — | — | — | — | -2.14 | — | -2.18 | — | — | -0.61 |
| Debt / FCF | — | — | — | — | — | — | — | -0.74 | — | — | -0.16 |
| Interest Coverage | — | — | -4.87 | — | — | 3366.69 | — | — | -4960.63 | -4120.15 | 1073.33 |
Short-term solvency ratios and asset-utilisation metrics
Xencor, Inc.'s current ratio of 6.25x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 7.36x to 6.25x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.25 | 6.25 | 6.61 | 7.36 | 10.58 | 6.00 | 5.27 | 8.39 | 5.86 | 2.28 | 1.33 |
| Quick Ratio | 6.25 | 6.25 | 6.61 | 7.36 | 10.58 | 6.00 | 5.27 | 8.39 | 5.86 | 2.28 | 1.33 |
| Cash Ratio | 4.54 | 4.54 | 5.69 | 7.01 | 9.76 | 4.72 | 4.98 | 7.92 | 5.47 | 2.21 | 1.22 |
| Asset Turnover | — | — | 0.12 | 0.18 | 0.19 | 0.33 | 0.17 | 0.23 | 0.07 | 0.09 | 0.20 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | 201.01 | 23.60 | 64.31 | 88.07 | 71.23 | 57.71 | 91.58 | 11.67 | 35.93 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Xencor, Inc. returns 0.1% to shareholders annually primarily through share buybacks.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | 3.4% | — | 1.3% | — | — | 2.1% |
| FCF Yield | — | — | — | — | — | — | — | 2.7% | — | — | 8.2% |
| Buyback Yield | 0.1% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.1% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $74M | $65M | $61M | $60M | $60M | $57M | $58M | $54M | $47M | $42M |
Compare XNCR with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| XNCRYou | $918M | -10.3 | — | — | — | — | -9.5% | — | — |
| REGN | $108B | 18.8 | 21.6 | 26.4 | 86.3% | 25.7% | 14.9% | 12.4% | 0.6 |
| CNTA | $4B | -13.0 | — | — | — | — | -73.9% | -91.8% | — |
| IMNM | $2B | -4.4 | — | — | 100.0% | -3382.4% | -194.6% | -700.3% | — |
| CLDX | $2B | -7.7 | — | — | 100.0% | -19160.0% | -40.6% | -35.2% | — |
| RXRX | $2B | -2.5 | — | — | 5.0% | -867.9% | -59.5% | -95.8% | — |
| NRIX | $2B | -5.2 | — | — | 77.5% | -340.2% | -49.6% | -54.0% | — |
| ROIV | $1B | -120.6 | — | — | 96.9% | -3453.3% | -3.0% | -50.4% | — |
| ABCL | $1B | -7.4 | — | — | — | -289.0% | -14.5% | -16.8% | — |
| ARVN | $975M | -10.4 | — | — | -151.8% | -45.1% | -16.2% | -23.1% | — |
| TECX | $439M | -6.0 | — | — | — | — | -206.6% | — | — |
| Healthcare Median | — | 23.7 | 13.8 | 18.8 | 65.8% | -6.3% | -37.3% | -15.0% | 3.1 |
Peers based on L4 peer group classification. Compare multiple stocks →
Includes 30+ ratios · 15 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how XNCR stacks up against sector leader Regeneron Pharmaceuticals, Inc..
Start ComparisonXencor, Inc.'s current P/E ratio is -10.3x. The historical average is 50.3x.
Xencor, Inc.'s return on equity (ROE) is -9.5%. The historical average is -27.1%.
Based on historical data, Xencor, Inc. is trading at a P/E of -10.3x. Compare with industry peers and growth rates for a complete picture.